# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Rudolph (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML036-SYN-TD
- Date: 1994-10-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Haynes-Whitaker, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

MRI result after chemoradiation and the first day of adjuvant temozolomide. **S**

## History of present illness

Ms. Rudolph returns four weeks after the end of radiotherapy. The MRI two days ago shows thin, smooth enhancement along the edge of the resection cavity and no new or nodular enhancement, with less swelling than after surgery. Her energy has improved over the past two weeks and she is working half days. The scalp has healed. She saw the palliative care team eleven days ago, talked through her symptoms, her understanding of the illness and what matters most to her, and completed an advance directive naming a health care agent. The tumor-treating fields device was fitted yesterday and she wore it overnight. She has had no headache, seizure, change in speech, weakness or fall. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| MRI | Treatment-related change only; no progression (RANO 2.0) |
| Energy | Improving; half days at work |
| Palliative care | Seen eleven days ago; advance directive completed |
| Today | Adjuvant temozolomide cycle 1, day 1; tumor-treating fields started |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons, less than before; no fever |
| Gastrointestinal | Negative | No nausea, vomiting or constipation |
| Integumentary | Negative | Scalp healed; no redness under the new arrays this morning |
| Neurological | Negative | No headache, seizure, speech change or weakness |
| Hematologic and lymphatic | Negative | No bruising or bleeding |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Negative | More hopeful; PHQ-9 6; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia **S**
- Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea **S**
- Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6 **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 66.6 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Hemoglobin: 12.2 g/dL; White cell count: 4.4 10*3/uL; Absolute neutrophil count: 2.9 10*3/uL; Absolute lymphocyte count: 0.6 10*3/uL (low); Platelets: 168 10*3/uL; Creatinine: 0.81 mg/dL; eGFR (CKD-EPI 1989): 86 mL/min/1.73 m²; ALT: 31 U/L; AST: 27 U/L; Total bilirubin: 0.5 mg/dL; Glucose: 91 mg/dL; Karnofsky Performance Status: 80; PHQ-9: 6. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.1 g/dL at baseline, 12.2 g/dL at this visit **S**
- White cell count: 7.1 10*3/uL at baseline, 4.4 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 168 10*3/uL at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.81 mg/dL at this visit **S**
- eGFR (CKD-EPI 1989): 80 mL/min/1.73 m² at baseline, 86 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 91 mg/dL at this visit **S**
- Karnofsky Performance Status: 80 at baseline, 80 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 66.6 kg; blood pressure 120/76, pulse 74 |
| Head | Scalp shaved for the arrays; skin intact; radiation dermatitis resolved |
| Neurological | Speech fluent; strength full in all four limbs; gait steady |
| Extremities | No leg swelling or calf tenderness |
| Psychiatric | Engaged and composed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Glioblastoma, IDH-wildtype, MGMT methylated, starting adjuvant temozolomide with tumor-treating fields** (C71.1). The first MRI after chemoradiation shows treatment-related change without progression by RANO 2.0 and becomes the new baseline; any new enhancement in the next few months would be weighed against pseudoprogression before changing treatment. Neutrophils 2.9 and platelets 168 allow cycle 1, and ALT 31 and AST 27 U/L are back in range. Cycle 1 of temozolomide at 150 mg/m2 (280 mg) on days 1 to 5 starts tonight. Tumor-treating fields started yesterday, at least 18 hours a day. **S**
   - Temozolomide 280 mg at bedtime on days 1 to 5, with ondansetron first.
   - Blood count on day 22; escalate to 200 mg/m2 for cycle 2 if counts and tolerance allow.
   - Tumor-treating fields at least 18 hours a day; scalp checks at each array change.
   - MRI every two to three months during adjuvant treatment.
2. **Vasogenic cerebral edema** (G93.6). Resolved on MRI, off steroids for two months. **S**
   - Problem resolved.
3. **Lymphopenia from temozolomide, grade 2** (D72.810). Absolute lymphocytes 0.6; still grade 2. **S**
   - Continue sulfamethoxazole-trimethoprim three times a week.
4. **Late effects of childhood poliomyelitis** (B91). No falls; legs strong; walking daily. **S**
   - Continue home exercises.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | MRI of the brain after chemoradiation (RANO 2.0) | About four weeks after radiotherapy, then every two to three months | Up to date | Two days ago: treatment-related change, no progression; new baseline |
| Imaging | Next MRI of the brain | Every two to three months during adjuvant treatment | Due | After cycle 2 |
| Laboratory | Blood count with neutrophils, lymphocytes and platelets | Before each adjuvant cycle and on day 22 | Completed today | Hemoglobin 12.2 g/dL, white cells 4.4, neutrophils 2.9, lymphocytes 0.6, platelets 168: cycle 1 can start |
| Laboratory | Day-22 blood count | Day 22 of each adjuvant cycle, then weekly until neutrophils exceed 1.5 | Due | Booked for the preventive visit three weeks from now |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Before each cycle and midway through cycle 1 | Completed today | ALT 31, AST 27 U/L, bilirubin 0.5 mg/dL; the grade 1 rise has resolved |
| Laboratory | Liver tests midway through adjuvant cycle 1 | Midway through the first cycle | Deferred | A planned deviation: to spare her an extra trip, the mid-cycle liver tests will be drawn with the day-22 blood count, about a week after the label's midpoint. Today's liver tests are normal after a grade 1 rise. Outcome and action to be recorded at that draw |
| Laboratory | Kidney function and glucose | Each visit | Completed today | Creatinine 0.81 mg/dL, eGFR 86; glucose 91 mg/dL |
| Medication safety | Pneumocystis pneumonia prophylaxis | Until lymphopenia is grade 1 or better | Completed today | Continues for lymphocytes 0.6 |
| Medication safety | Antiemetic before temozolomide | Each dose | Completed today | Ondansetron before each bedtime dose |
| Self-management | Tumor-treating fields: wear time and scalp care | Each visit while in use | Completed today | Started yesterday; at least 18 hours a day; shave and shift arrays at each change; report redness or blisters |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | No deficit |
| Medication safety | Seizure history and antiseizure drug need | Each visit | Not indicated | No seizure; no antiseizure drug |
| Examination | Signs of leg clot or pulmonary embolism | Each visit | Completed today | None |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 80 |
| Referral | Palliative care | Early and ongoing | Up to date | Seen eleven days ago; advance directive completed; follow-up in two months |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; legs strong; walking daily |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 6; no thoughts of self-harm |

## Goal progress

- MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation. Outcome by 1994-07-02: MRI the next morning; consultation three days after the first visit. **S**
- Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength. Outcome by 1994-07-29: Gross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normal. **S**
- Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule. Outcome by 1994-09-14: Started 26 days after surgery; 30 fractions and 42 days of temozolomide completed without a break. **S**
- Dexamethasone tapered off within five weeks of surgery, with glucose back to normal. Outcome by 1994-09-14: Off dexamethasone five weeks after surgery; glucose 96 mg/dL afterwards. **S**
- No falls, and walking independently, through treatment. Outcome by 1994-10-09: No falls; walks independently, with a cane only on uneven ground; home exercise program continued. **S**
- Palliative care involved and her wishes recorded before adjuvant treatment begins. Outcome by 1994-10-09: Palliative care consultation and advance directive completed eleven days before adjuvant cycle 1. **S**

## Medication changes

- Started: Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6 **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026), National Comprehensive Cancer Network
- Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021), European Association of Neuro-Oncology
- Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005), New England Journal of Medicine
- Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017), JAMA
- Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023), Response Assessment in Neuro-Oncology working group (Journal of Clinical Oncology)
- TEMODAR (temozolomide) capsules, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Merck Sharp & Dohme label)
- Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021), Society for Neuro-Oncology and European Association of Neuro-Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
- Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006), European Federation of Neurological Societies
- CMID: Clinical Monitoring Intelligence Database, depression monograph (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Temozolomide days 1 to 5 from tonight. Preventive visit and day-22 blood count with liver tests in three weeks. Neuro-oncology review and MRI after cycle 2. Call for fever, bruising, a seizure, headache, new weakness or scalp blisters. **S**
- Next scheduled visit 1994-10-29: periodic adult preventive visit. **S**
